Copyright Reports & Markets. All rights reserved.

Global and China Glioblastoma Multiforme Treatment (GBM) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Chemotherapy
    • 1.2.3 Radiotherapy
    • 1.2.4 Gene therapy
    • 1.2.5 Molecular biotechnology
  • 1.3 Market by Application
    • 1.3.1 Global Glioblastoma Multiforme Treatment (GBM) Market Share by Application: 2020 VS 2026
    • 1.3.2 Bevacozumab
    • 1.3.3 Carmustine
    • 1.3.4 Temozolomide
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Glioblastoma Multiforme Treatment (GBM) Market Perspective (2015-2026)
  • 2.2 Global Glioblastoma Multiforme Treatment (GBM) Growth Trends by Regions
    • 2.2.1 Glioblastoma Multiforme Treatment (GBM) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Glioblastoma Multiforme Treatment (GBM) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Glioblastoma Multiforme Treatment (GBM) Players by Market Size
    • 3.1.1 Global Top Glioblastoma Multiforme Treatment (GBM) Players by Revenue (2015-2020)
    • 3.1.2 Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Players (2015-2020)
  • 3.2 Global Glioblastoma Multiforme Treatment (GBM) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Glioblastoma Multiforme Treatment (GBM) Revenue
  • 3.4 Global Glioblastoma Multiforme Treatment (GBM) Market Concentration Ratio
    • 3.4.1 Global Glioblastoma Multiforme Treatment (GBM) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme Treatment (GBM) Revenue in 2019
  • 3.5 Key Players Glioblastoma Multiforme Treatment (GBM) Area Served
  • 3.6 Key Players Glioblastoma Multiforme Treatment (GBM) Product Solution and Service
  • 3.7 Date of Enter into Glioblastoma Multiforme Treatment (GBM) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Glioblastoma Multiforme Treatment (GBM) Breakdown Data by Type (2015-2026)

  • 4.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Type (2015-2020)
  • 4.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Type (2021-2026)

5 Glioblastoma Multiforme Treatment (GBM) Breakdown Data by Application (2015-2026)

  • 5.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Application (2015-2020)
  • 5.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Glioblastoma Multiforme Treatment (GBM) Market Size (2015-2026)
  • 6.2 North America Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2015-2020)
  • 6.3 North America Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2015-2020)
  • 6.4 North America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Glioblastoma Multiforme Treatment (GBM) Market Size (2015-2026)
  • 7.2 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2015-2020)
  • 7.3 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2015-2020)
  • 7.4 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Glioblastoma Multiforme Treatment (GBM) Market Size (2015-2026)
  • 8.2 China Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2015-2020)
  • 8.3 China Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2015-2020)
  • 8.4 China Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Glioblastoma Multiforme Treatment (GBM) Market Size (2015-2026)
  • 9.2 Japan Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2015-2020)
  • 9.3 Japan Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2015-2020)
  • 9.4 Japan Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Glioblastoma Multiforme Treatment (GBM) Market Size (2015-2026)
  • 10.2 Southeast Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Merck
    • 11.1.1 Merck Company Details
    • 11.1.2 Merck Business Overview
    • 11.1.3 Merck Glioblastoma Multiforme Treatment (GBM) Introduction
    • 11.1.4 Merck Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2015-2020))
    • 11.1.5 Merck Recent Development
  • 11.2 Teva Pharmaceutical
    • 11.2.1 Teva Pharmaceutical Company Details
    • 11.2.2 Teva Pharmaceutical Business Overview
    • 11.2.3 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Introduction
    • 11.2.4 Teva Pharmaceutical Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2015-2020)
    • 11.2.5 Teva Pharmaceutical Recent Development
  • 11.3 Arbor Pharmaceuticals
    • 11.3.1 Arbor Pharmaceuticals Company Details
    • 11.3.2 Arbor Pharmaceuticals Business Overview
    • 11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Introduction
    • 11.3.4 Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2015-2020)
    • 11.3.5 Arbor Pharmaceuticals Recent Development
  • 11.4 Sun Pharmaceutical
    • 11.4.1 Sun Pharmaceutical Company Details
    • 11.4.2 Sun Pharmaceutical Business Overview
    • 11.4.3 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Introduction
    • 11.4.4 Sun Pharmaceutical Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2015-2020)
    • 11.4.5 Sun Pharmaceutical Recent Development
  • 11.5 Roche
    • 11.5.1 Roche Company Details
    • 11.5.2 Roche Business Overview
    • 11.5.3 Roche Glioblastoma Multiforme Treatment (GBM) Introduction
    • 11.5.4 Roche Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2015-2020)
    • 11.5.5 Roche Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Glioblastoma Multiforme Treatment (GBM) Scope and Market Size
    Glioblastoma Multiforme Treatment (GBM) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Glioblastoma Multiforme Treatment (GBM) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Chemotherapy
    Radiotherapy
    Gene therapy
    Molecular biotechnology

    Market segment by Application, split into
    Bevacozumab
    Carmustine
    Temozolomide

    Based on regional and country-level analysis, the Glioblastoma Multiforme Treatment (GBM) market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Glioblastoma Multiforme Treatment (GBM) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Merck
    Teva Pharmaceutical
    Arbor Pharmaceuticals
    Sun Pharmaceutical
    Roche
    ...

    Buy now